| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5e77d402d3f3211830c60b57d9d71e8 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08 |
| filingDate |
2018-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a22399df1fd24969d6deafb18e1f5d1 |
| publicationDate |
2019-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019021196-A1 |
| titleOfInvention |
MESEMBRENOL AND / OR MESEMBRANOL FOR THE PROPHYLAXIS AND TREATMENT OF PATIENTS SUFFERING FROM EPILEPSY AND RELATED DISEASES |
| abstract |
The invention relates to the alkaloids mesembranol or mesembrenol, or salts or complexes of pharmaceutical quality thereof, for use in the prophylaxis or treatment of diseases responsive to treatment with an AMPA receptor agonist (α-amino-3-acid). -hydroxy-5-methyl-4-isoxazolepropionic acid). Prophylaxis or treatment alleviates AMPA-mediated neurotransmission in the patient's hippocampus. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023166304-A1 |
| priorityDate |
2017-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |